139 related articles for article (PubMed ID: 17012888)
1. Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales.
Trotter CL; Edmunds WJ; Ramsay ME; Miller E
Hum Vaccin; 2006; 2(2):68-73. PubMed ID: 17012888
[TBL] [Abstract][Full Text] [Related]
2. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model.
Trotter CL; Edmunds WJ
Med Decis Making; 2006; 26(1):38-47. PubMed ID: 16495199
[TBL] [Abstract][Full Text] [Related]
3. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.
Campbell H; Andrews N; Borrow R; Trotter C; Miller E
Clin Vaccine Immunol; 2010 May; 17(5):840-7. PubMed ID: 20219881
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.
Trotter CL; Andrews NJ; Kaczmarski EB; Miller E; Ramsay ME
Lancet; 2004 Jul 24-30; 364(9431):365-7. PubMed ID: 15276396
[TBL] [Abstract][Full Text] [Related]
5. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.
Souza AR; Maruyama CM; Sáfadi MA; Lopes MH; Azevedo RS; Findlow H; Bai X; Borrow R; Weckx LY
Vaccine; 2016 Aug; 34(36):4327-34. PubMed ID: 27395566
[TBL] [Abstract][Full Text] [Related]
6. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination.
Trotter CL; Gay NJ; Edmunds WJ
Am J Epidemiol; 2005 Jul; 162(1):89-100. PubMed ID: 15961591
[TBL] [Abstract][Full Text] [Related]
7. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact.
Christensen H; Hickman M; Edmunds WJ; Trotter CL
Vaccine; 2013 May; 31(23):2638-46. PubMed ID: 23566946
[TBL] [Abstract][Full Text] [Related]
8. Impact of meningococcal C conjugate vaccine in the UK.
Balmer P; Borrow R; Miller E
J Med Microbiol; 2002 Sep; 51(9):717-722. PubMed ID: 12358061
[TBL] [Abstract][Full Text] [Related]
9. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity.
Maiden MC; Ibarz-Pavón AB; Urwin R; Gray SJ; Andrews NJ; Clarke SC; Walker AM; Evans MR; Kroll JS; Neal KR; Ala'aldeen DA; Crook DW; Cann K; Harrison S; Cunningham R; Baxter D; Kaczmarski E; Maclennan J; Cameron JC; Stuart JM
J Infect Dis; 2008 Mar; 197(5):737-43. PubMed ID: 18271745
[TBL] [Abstract][Full Text] [Related]
10. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination.
Bijlsma MW; Brouwer MC; Spanjaard L; van de Beek D; van der Ende A
Clin Infect Dis; 2014 Nov; 59(9):1216-21. PubMed ID: 25069869
[TBL] [Abstract][Full Text] [Related]
11. Serogroup A meningococcal conjugate vaccines in Africa.
Kristiansen PA; Jørgensen HJ; Caugant DA
Expert Rev Vaccines; 2015; 14(11):1441-58. PubMed ID: 26358167
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
[TBL] [Abstract][Full Text] [Related]
13. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.
Trotter CL; Edmunds WJ
BMJ; 2002 Apr; 324(7341):809. PubMed ID: 11934772
[TBL] [Abstract][Full Text] [Related]
14. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.
Trotter CL; Maiden MC
Expert Rev Vaccines; 2009 Jul; 8(7):851-61. PubMed ID: 19538112
[TBL] [Abstract][Full Text] [Related]
15. Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?
Findlow H; Borrow R
Hum Vaccin Immunother; 2015; 11(6):1501-6. PubMed ID: 25912095
[TBL] [Abstract][Full Text] [Related]
16. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis.
Ramsay ME; Andrews NJ; Trotter CL; Kaczmarski EB; Miller E
BMJ; 2003 Feb; 326(7385):365-6. PubMed ID: 12586669
[No Abstract] [Full Text] [Related]
17. Estimating the burden of serogroup C meningococcal disease in England and Wales.
Davison KL; Ramsay ME; Crowcroft NS; Lieftucht A; Kaczmarski EB; Trotter CL; Gungabissoon U; Begg NT
Commun Dis Public Health; 2002 Sep; 5(3):213-9. PubMed ID: 12434691
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
[TBL] [Abstract][Full Text] [Related]
19. Can we control all-cause meningococcal disease in Europe?
Sadarangani M; Pollard AJ
Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S103-S112. PubMed ID: 27129415
[TBL] [Abstract][Full Text] [Related]
20. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.
Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R
Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
